8-K: Precigen Sells FCX-007 Related Assets to Paragon Biosciences Affiliate for $8.5 Million

Precigen, Inc. has completed the sale of assets related to its former collaboration on the FCX-007 product candidate to an affiliate of Paragon Biosciences, LLC for $8.5 million.

Summary

• Precigen, Inc. has sold certain assets, including intellectual property and royalty rights, related to FCX-007 to Innovator 21, LLC, an affiliate of Paragon Biosciences, LLC.
• FCX-007 is a clinical-stage product candidate for the treatment of Epidermolysis Bullosa (EB) and/or Dystrophic Epidermolysis Bullosa (DEB), being developed by Castle Creek Biosciences, LLC, a portfolio company of Paragon.
• Precigen received a cash payment of $8.5 million at the closing of the asset sale on December 24, 2024.
• Precigen had previously collaborated with Castle Creek on FCX-007, but the collaboration was terminated in March 2020.
• Following the sale, Precigen has no further rights or obligations related to FCX-007 or its previous collaboration with Castle Creek.
• The company intends to use the proceeds for working capital and general corporate purposes.

Sentiment

Score: 4

Explanation: The sale provides immediate cash, but the relatively low price and loss of potential future royalties suggest a slightly negative sentiment.

Positives

• The sale provides Precigen with an immediate cash injection of $8.5 million.
• The sale allows Precigen to divest from a non-core asset and focus on other projects.
• The transaction eliminates any future obligations or liabilities related to the terminated collaboration with Castle Creek.

Negatives

• Precigen loses potential future royalty income from the commercialization of FCX-007.
• The sale price of $8.5 million may be considered low if FCX-007 proves to be highly successful.

Risks

• The $8.5 million received may not be sufficient to meet Precigen's working capital needs or fund its other projects adequately.
• There is a risk that Precigen's decision to sell the FCX-007 assets may be viewed negatively by investors if the product candidate ultimately proves successful.

Future Outlook

The document does not explicitly provide forward-looking statements, but it implies that Precigen will use the proceeds from the sale to support its ongoing operations and potentially invest in other projects.

Management Comments

• The document does not contain any direct quotes from management. However, the signature of Donald P. Lehr, Chief Legal Officer, indicates management's approval of the transaction.

Industry Context

This announcement reflects a trend in the biotechnology industry where companies often divest non-core assets or out-license technologies to focus on their core strengths and streamline operations. It also highlights the role of companies like Paragon Biosciences in acquiring and developing promising technologies.

Comparison to Industry Standards

• Compared to similar transactions, the $8.5 million sale price appears relatively modest. For instance, in 2023, Amryt Pharma was acquired by Chiesi Farmaceutici for up to $1.48 billion, including milestone payments, highlighting the potential value of successful EB treatments.
• However, the specific value of FCX-007 is uncertain at this clinical stage, and the sale price may reflect its current development status and perceived risk.
• Other companies developing treatments for EB include Abeona Therapeutics and Krystal Biotech, both of which have market capitalizations significantly higher than the $8.5 million sale price, suggesting that the market may value these assets higher.

Related Party Transactions

• The sale of assets to Innovator 21, LLC, an affiliate of Paragon Biosciences, LLC, could be considered a related party transaction since Castle Creek Biosciences, the developer of FCX-007, is a portfolio company of Paragon.

Stakeholder Impact

• Shareholders: The impact on shareholders is uncertain; the immediate cash is positive, but the loss of potential future royalties could be negative.
• Employees: No direct impact on employees is mentioned.
• Customers: No direct impact on customers is mentioned.
• Suppliers: No direct impact on suppliers is mentioned.
• Creditors: The sale could be viewed positively by creditors as it improves Precigen's short-term liquidity.

Next Steps

• Precigen will use the proceeds from the sale for working capital and general corporate purposes.
• Castle Creek Biosciences will continue to develop FCX-007.

Key Dates

Keywords

Precigen, FCX-007, Asset Acquisition, Paragon Biosciences, Castle Creek Biosciences, Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa, Royalty Rights, Clinical Stage, Biotechnology